title: Effect of short-term tibolone treatment on risk markers for cardiovascular disease in healthy postmenopausal women: a randomized controlled study.
abstract: OBJECTIVE
  The aim of this prospective randomized controlled cross sectional study was to evaluate the effect of a six month tibolone treatment in healthy postmenopausal women on biochemical CVD markers by calculating the changes of the blood serum levels of total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (Tg), high-sensitivity C-reactive protein (hsCRP), homocysteine (Hcy), and endothelin-1 (ET-1) at the beginning of the treatment and after six months.
  
  
  METHODS
  Fifty-two healthy postmenopausal women were enrolled in a prospective, randomized, case-controlled outpatient trial. Group 1 (n = 26) received 2,5 mg/d tibolone for six months, while Group 2 (n = 26) received no treatment. Serum levels ofTC, LDL, HDL, Tg, hsCRP, Hcy, and ET-1 were evaluated at baseline and after six months.
  
  
  RESULTS
  The two groups did not statistically differ at baseline characteristics. In Group 1 tibolone treatment decreased significantly TC (p = 0.01), HDL (p < 0.001), and Tg (p < 0.001) serum levels while a significant increase ofhsCRP (p < 0.001) was observed. Finally no changes were noticed on LDL, Hcy, and ET-1 serum levels. Regarding Group 2, no changes were observed.
  
  
  CONCLUSIONS
  Short-term tibolone treatment in healthy postmenopausal women exerts a mixed action, acting beneficially in some markers (TC, LDL, Tg, Hcy, and ET-1) where as detrimentally in others (HDL, hsCRP).
authors.affiliation: First Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, "Papageorghiou" General Hospital of Thessaloniki, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Traianos
authors.affiliation: First Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, "Papageorghiou" General Hospital of Thessaloniki, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Vavilis
authors.affiliation: First Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, "Papageorghiou" General Hospital of Thessaloniki, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Makedos
authors.affiliation: Third Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, "Ippokrateio" General Hospital of Thessaloniki, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Karkanaki
authors.affiliation: Third Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, "Ippokrateio" General Hospital of Thessaloniki, Greece.
authors.forename: K
authors.initials: K
authors.lastname: Ravanos
authors.affiliation: Third Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, "Ippokrateio" General Hospital of Thessaloniki, Greece.
authors.forename: N
authors.initials: N
authors.lastname: Prapas
authors.affiliation: First Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, "Papageorghiou" General Hospital of Thessaloniki, Greece.
authors.forename: B C
authors.initials: BC
authors.lastname: Tarlatzis
mesh_terms: D015415:Biomarkers / Q000097:blood*; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000097:blood* / Q000209:etiology / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood; D008875:Middle Aged; D009652:Norpregnenes / Q000008:administration & dosage* / Q000009:adverse effects; D017698:Postmenopause / Q000097:blood*; D011446:Prospective Studies; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D015415:Biomarkers; D008075:Lipoproteins, HDL; D009652:Norpregnenes; D014280:Triglycerides; D002097:C-Reactive Protein; D002784:Cholesterol; C027385:tibolone